Newswise — After months of public acrimony over the Alzheimer’s Disease Cooperative Study, the University of California, San Diego, has announced that Howard Feldman will take over the battered clinical trials network as part of a broader appointment to its School of Medicine. Feldman, currently the executive associate dean for research at the University of British Columbia in Vancouver, is among the most highly regarded clinician-researchers in the field of age-related neurodegenerative disease, and an Alzforum advisor.
When the ADCS’s previous director, Paul Aisen, abruptly decamped to the University of Southern California last June, he set off a fight over control of this federally funded, 58-center clinical trials network that devolved into an ongoing court battle. In the process, the ADCS lost its flagship clinical trial, a prevention study called A4, and other treatment trials, but Feldman has plenty of ideas—and the power—to revive its pipeline.
Feldman envisions a future in which the ADCS stimulates and executes innovative designs, outcome measures, and other building blocks of successful trials for the first time, while also interacting in many more ways with the Alzheimer’s Disease Research Center and research groups st UCSD and beyond than had been the case in recent years. Read his interview with Gabrielle Strobel.
About UsFounded in 1996, Alzforum is a news and information resource website dedicated to helping researchers accelerate discovery and advance development of diagnostics and treatments for Alzheimer’s disease and related disorders.
Our site expands the traditional mode of scientific communication by reporting the latest scientific findings and industry news with insightful analysis that puts breaking news into context. We advance research by developing open-access databases of curated, highly specific scientific content to visualize and facilitate the exploration of complex data. Alzforum is a platform to disseminate the evolving knowledge around basic, translational, and clinical research in the field of AD.
Alzforum is supported by a team with backgrounds in science, journalism, information technology, design, and data science. Together with a distinguished Scientific Advisory Board, and the active participation of a global network of scientists, we strive to produce unbiased content to a rigorous editorial standard.
Alzforum is operated by the Biomedical Research Forum (BRF) LLC. BRF is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies.Alzforum does not endorse any specific product or scientific approach.
RSS